STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Organogenesis Holdings Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Organogenesis Holdings, Inc. Schedule 13G shows First Light Asset Management, LLC and Mathew P. Arens report joint beneficial ownership of common stock. The Manager is reported to beneficially own 8,061,404 shares (representing 6.35% of the class) while Mr. Arens is reported to beneficially own 8,309,404 shares (6.55%), including 231,000 shares held directly with sole voting and dispositive power. The filing is made under Rule 13d-1(b) and includes a joint filing agreement.

Positive

  • Disclosure of material stake: First Light reports 8,061,404 shares (6.35%) and Mr. Arens reports 8,309,404 shares (6.55%), both above 5% thresholds.
  • Clear allocation of voting/dispositive power: Filing specifies sole versus shared voting and disposition (231,000 shares sole by Mr. Arens; shared power for larger holdings).
  • Filed under Rule 13d-1(b): Certification states holdings are in the ordinary course of business and not for the purpose of changing control.

Negative

  • None.

Insights

TL;DR Joint disclosure shows institutional adviser and CEO-level individual each above 5% ownership, a notable ownership concentration.

The filing discloses that First Light Asset Management holds 8,061,404 shares (6.35%) via managed accounts and private funds while Mathew P. Arens, as managing member, is reported with 8,309,404 shares (6.55%), including 231,000 shares held directly with sole voting and dispositive power. This is a Schedule 13G filed under Rule 13d-1(b), indicating passive investment intent per the certification. The positions disclosed are sufficiently large to be material to holders' ownership profiles but the filing explicitly states shares are held in the ordinary course of business and not to influence control.

TL;DR Disclosure clarifies allocation of voting and dispositive power between the adviser and its principal, aiding governance transparency.

The Schedule 13G clarifies that shared voting and dispositive power of 8,061,404 shares is exercised by First Light as adviser, while Mr. Arens reports both shared control (8,078,404 shares) and sole control over 231,000 shares. The joint filing and certification language indicate a passive posture under Rule 13d-1(b). For governance, the filing documents an identifiable concentrated stake and differentiates sole versus shared authorities, which is important for board and shareholder oversight but does not assert any change in control intentions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



First Light Asset Management, LLC
Signature:/s/ Kurt T. Peterson
Name/Title:Kurt T. Peterson/Chief Compliance Officer
Date:08/14/2025
Mathew P. Arens
Signature:/s/ Mathew P. Arens
Name/Title:Mathew P. Arens/Chief Executive Officer
Date:08/14/2025
Exhibit Information

Exhibit A: Joint Filing Agreement

FAQ

How many Organogenesis (ORGO) shares does First Light Asset Management report owning?

First Light Asset Management reports beneficial ownership of 8,061,404 shares, representing 6.35% of the class.

What is Mathew P. Arens' reported ownership in ORGO?

Mathew P. Arens reports beneficial ownership of 8,309,404 shares, representing 6.55%, including 231,000 shares with sole voting and dispositive power.

Under what rule was this Schedule 13G filed?

The Schedule 13G was filed pursuant to Rule 13d-1(b), indicating a passive reporting category.

Does the filing state the shares are intended to influence control of ORGO?

No. The certification states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Where are the reporting persons' principal offices located?

The reporting persons' principal business office is listed as 3300 Edinborough Way, Suite 201, Edina, MN 55435.
Organogenesis Hldgs Inc

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Latest SEC Filings

ORGO Stock Data

709.44M
67.16M
46.69%
55.12%
8.03%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CANTON